Histrelin
From Wikipedia, the free encyclopedia
Histrelin
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | 76712-82-8 |
ATC code | H01CA03 |
PubChem | ? |
Chemical data | |
Formula | C66H86N18O12 |
Mol. weight | 1323.5 g/mol |
Pharmacokinetic data | |
Bioavailability | 92% |
Protein binding | 70% |
Metabolism | Hepatic |
Half life | 4 hours |
Excretion | Undetermined |
Therapeutic considerations | |
Pregnancy cat. |
X(US) |
Legal status |
℞-only(US) |
Routes | Subcutaneous implant |
Histrelin acetate is an injectable gonadotropin releasing hormone antagonist (GnRH antagonist). It stops the production of sex hormones (testosterone and oestrogen).
Histrelin is marketed by Valera Pharmaceuticals with the brand name Supprelin.
[edit] Indications
Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. In addition, histrelin is used to treat systemic precocious puberty.
It is available as a daily intramuscular injection. A 12-month depot injection (Supprelin-LA) is currently undergoing the approval process with the U.S. Food and Drug Administration.